Age
Item
1. subjects of either sex, 14-65 years of age;
boolean
C0001779 (UMLS CUI [1])
Nephrotic Syndrome | Hypoalbuminemia | Heavy proteinuria
Item
2. diagnosis of nephrotic syndrome with hypoalbuminemia (<3.0g/dl) and heavy proteinuria (> 3.5g/24hr);
boolean
C0027726 (UMLS CUI [1])
C0239981 (UMLS CUI [2])
C4022830 (UMLS CUI [3])
Informed Consent | Informed Consent Guardian
Item
3. provision of written informed consent by subject or guardian;
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C1274041 (UMLS CUI [2,2])
Nephrotic Syndrome refractory
Item
4. refractory nephrotic syndrome:
boolean
C0027726 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
Steroid-resistant nephrotic syndrome | Persistent proteinuria | Prednisone mg/kg/day | Steroid-dependent nephrotic syndrome | Nephrotic Syndrome Recurrent | Steroid Dosage
Item
steroid resistant: persistence of proteinuria despite prednisone therapy 1mg/kg/d for 16 weeks; steroid dependent: ns recurs when steroid dosage decease.twice within 6 months, and 3 times within 1 year.
boolean
C0403397 (UMLS CUI [1])
C0477762 (UMLS CUI [2])
C0032952 (UMLS CUI [3,1])
C3665414 (UMLS CUI [3,2])
C0403398 (UMLS CUI [4])
C0027726 (UMLS CUI [5,1])
C2945760 (UMLS CUI [5,2])
C0038317 (UMLS CUI [6,1])
C0178602 (UMLS CUI [6,2])
Informed Consent Unable | Informed Consent Unwilling
Item
1. inability or unwillingness to provide written informed consent ;
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
Hypersensitivity Tacrolimus | Medical contraindication Tacrolimus | Hypersensitivity Cyclophosphamide | Medical contraindication Cyclophosphamide | Azathioprine allergy | Medical contraindication Azathioprine | Corticosteroids allergy | Medical contraindication Adrenal Cortex Hormones
Item
2. known hypersensitivity or contraindication to tacrolimus, cyclophosphamide, azathioprine, corticosteroids;
boolean
C0020517 (UMLS CUI [1,1])
C0085149 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0085149 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0010583 (UMLS CUI [3,2])
C1301624 (UMLS CUI [4,1])
C0010583 (UMLS CUI [4,2])
C0570721 (UMLS CUI [5])
C1301624 (UMLS CUI [6,1])
C0004482 (UMLS CUI [6,2])
C0571586 (UMLS CUI [7])
C1301624 (UMLS CUI [8,1])
C0001617 (UMLS CUI [8,2])
Therapeutic immunosuppression | mycophenolate mofetil | Cyclophosphamide | Cyclosporine | Methotrexate
Item
3. usage of immunosuppression therapy (mmf, ctx, cysa, mtx ect) for more than 1 week within 1 month prior to first randomization;
boolean
C0021079 (UMLS CUI [1])
C0209368 (UMLS CUI [2])
C0010583 (UMLS CUI [3])
C0010592 (UMLS CUI [4])
C0025677 (UMLS CUI [5])
Pregnancy | Breast Feeding | Contraceptive methods Inadequate
Item
4. pregnancy, nursing or use of a non-reliable method of contraception;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3,1])
C0205412 (UMLS CUI [3,2])
Dialysis Continuous
Item
5. continuous dialysis starting more than 2 weeks before randomization into the induction phase and/or continuous dialysis with an anticipated duration of more than 8 weeks;
boolean
C0011946 (UMLS CUI [1,1])
C0549178 (UMLS CUI [1,2])
Kidney Transplant | Kidney Transplant Planned
Item
6. previous kidney transplant or planted transplant;
boolean
C0022671 (UMLS CUI [1])
C0022671 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Creatinine measurement, serum
Item
7. scr > 4mg/dl (353umol/l);
boolean
C0201976 (UMLS CUI [1])
Hepatitis | Liver Dysfunction
Item
8. active hepatitis, with liver dysfunction;
boolean
C0019158 (UMLS CUI [1])
C0086565 (UMLS CUI [2])
Diabetes Mellitus
Item
9. diagnosed dm;
boolean
C0011849 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
10. participation in another clinic trial and/or receipt of investigational drugs within 4 weeks prior to screening .
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])